ELUT

SEC source: 0001415889-22-002860 · form4-03102022_050359.xml · derivative · entry 3

Ferguson Matthew · CIK 0001304079 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,700

Underlying: Class A Common Stock · 8,700 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F5 · derivative.exercise_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

F5 · derivative.expiration_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

SEC source: 0001415889-22-002860 · form4-03102022_050359.xml · derivative · entry 2

Ferguson Matthew · CIK 0001304079 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,000

Underlying: Class A Common Stock · 31,000 shares

Expires 2032-03-08

F3 · derivative.exercise_date: The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.

SEC source: 0001415889-22-002860 · form4-03102022_050359.xml · nonDerivative · entry 1

Ferguson Matthew · CIK 0001304079 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.

F2 · balance_after: Includes 4,552 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.

SEC source: 0001415889-22-002858 · form4-03102022_050316.xml · derivative · entry 3

Edwards Peter G · CIK 0001578376 · GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,625

Underlying: Class A Common Stock · 4,625 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F4 · derivative.exercise_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

F4 · derivative.expiration_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

SEC source: 0001415889-22-002858 · form4-03102022_050316.xml · derivative · entry 2

Edwards Peter G · CIK 0001578376 · GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,700

Underlying: Class A Common Stock · 8,700 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F3 · derivative.exercise_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

F3 · derivative.expiration_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

SEC source: 0001415889-22-002858 · form4-03102022_050316.xml · derivative · entry 1

Edwards Peter G · CIK 0001578376 · GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,000

Underlying: Class A Common Stock · 31,000 shares

Expires 2032-03-08

F1 · derivative.exercise_date: The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.

SEC source: 0001415889-22-002864 · form4-03102022_050359.xml · derivative · entry 5

LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,894

Underlying: Class A Common Stock · 39,894 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F7 · derivative.exercise_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

F7 · derivative.expiration_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

SEC source: 0001415889-22-002864 · form4-03102022_050359.xml · derivative · entry 4

LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,216

Underlying: Class A Common Stock · 4,072 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.

F6 · derivative.exercise_date: On March 8, 2021, the Reporting Person was granted 16,288 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022.

F6 · derivative.expiration_date: On March 8, 2021, the Reporting Person was granted 16,288 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022.

SEC source: 0001415889-22-002864 · form4-03102022_050359.xml · derivative · entry 3

LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,788

Underlying: Class A Common Stock · 37,788 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F5 · derivative.exercise_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

F5 · derivative.expiration_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

SEC source: 0001415889-22-002864 · form4-03102022_050359.xml · derivative · entry 2

LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,770

Underlying: Class A Common Stock · 138,770 shares

Expires 2032-03-08

F3 · derivative.exercise_date: The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.

SEC source: 0001415889-22-002864 · form4-03102022_050359.xml · nonDerivative · entry 1

LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,775

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.

F2 · balance_after: Includes 4,552 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.

SEC source: 0001415889-22-002868 · form4-03102022_050356.xml · derivative · entry 6

Englese Thomas · CIK 0001825799 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,390

Underlying: Class A Common Stock · 15,390 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F8 · derivative.exercise_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

F8 · derivative.expiration_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

SEC source: 0001415889-22-002868 · form4-03102022_050356.xml · derivative · entry 5

Englese Thomas · CIK 0001825799 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,812

Underlying: Class A Common Stock · 938 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.

F7 · derivative.exercise_date: On March 8, 2021, the Reporting Person was granted 3,750 restricted stock units, vesting in four substantially equal annual installments beginning in March 8, 2022.

F7 · derivative.expiration_date: On March 8, 2021, the Reporting Person was granted 3,750 restricted stock units, vesting in four substantially equal annual installments beginning in March 8, 2022.

SEC source: 0001415889-22-002868 · form4-03102022_050356.xml · derivative · entry 4

Englese Thomas · CIK 0001825799 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,700

Underlying: Class A Common Stock · 8,700 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F6 · derivative.exercise_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

F6 · derivative.expiration_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

SEC source: 0001415889-22-002868 · form4-03102022_050356.xml · derivative · entry 3

Englese Thomas · CIK 0001825799 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,000

Underlying: Class A Common Stock · 31,000 shares

Expires 2032-03-08

F4 · derivative.exercise_date: The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.

SEC source: 0001415889-22-002868 · form4-03102022_050356.xml · nonDerivative · entry 1

Englese Thomas · CIK 0001825799 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,883

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.

F2 · balance_after: Includes 857 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.

SEC source: 0001415889-22-002866 · form4-03102022_050352.xml · derivative · entry 5

Roberts Darryl · CIK 0001825892 · EVP, OPERATIONS & PRODUCT DEV.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,024

Underlying: Class A Common Stock · 17,024 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F7 · derivative.exercise_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

F7 · derivative.expiration_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

SEC source: 0001415889-22-002866 · form4-03102022_050352.xml · derivative · entry 4

Roberts Darryl · CIK 0001825892 · EVP, OPERATIONS & PRODUCT DEV.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,812

Underlying: Class A Common Stock · 938 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.

F6 · derivative.exercise_date: On March 8, 2021, the Reporting Person was granted 3,750 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022.

F6 · derivative.expiration_date: On March 8, 2021, the Reporting Person was granted 3,750 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022.

SEC source: 0001415889-22-002866 · form4-03102022_050352.xml · derivative · entry 3

Roberts Darryl · CIK 0001825892 · EVP, OPERATIONS & PRODUCT DEV.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,440

Underlying: Class A Common Stock · 10,440 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F5 · derivative.exercise_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

F5 · derivative.expiration_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

SEC source: 0001415889-22-002866 · form4-03102022_050352.xml · derivative · entry 2

Roberts Darryl · CIK 0001825892 · EVP, OPERATIONS & PRODUCT DEV.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,200

Underlying: Class A Common Stock · 37,200 shares

Expires 2032-03-08

F3 · derivative.exercise_date: The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.

SEC source: 0001415889-22-002866 · form4-03102022_050352.xml · nonDerivative · entry 1

Roberts Darryl · CIK 0001825892 · EVP, OPERATIONS & PRODUCT DEV.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.

F2 · balance_after: Includes 2,391 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.

SEC source: 0001415889-22-002862 · form4-03102022_050332.xml · derivative · entry 5

Riebman Jerome · CIK 0001825821 · CHIEF MEDICAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,758

Underlying: Class A Common Stock · 14,758 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F7 · derivative.exercise_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

F7 · derivative.expiration_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

SEC source: 0001415889-22-002862 · form4-03102022_050332.xml · derivative · entry 4

Riebman Jerome · CIK 0001825821 · CHIEF MEDICAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,343

Underlying: Class A Common Stock · 782 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.

F6 · derivative.exercise_date: On March 8, 2021, the Reporting Person was granted 3,125 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022.

F6 · derivative.expiration_date: On March 8, 2021, the Reporting Person was granted 3,125 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022.

SEC source: 0001415889-22-002862 · form4-03102022_050332.xml · derivative · entry 3

Riebman Jerome · CIK 0001825821 · CHIEF MEDICAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,700

Underlying: Class A Common Stock · 8,700 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.

F5 · derivative.exercise_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

F5 · derivative.expiration_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.

SEC source: 0001415889-22-002862 · form4-03102022_050332.xml · derivative · entry 2

Riebman Jerome · CIK 0001825821 · CHIEF MEDICAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,000

Underlying: Class A Common Stock · 31,000 shares

Expires 2032-03-08

F3 · derivative.exercise_date: The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.

SEC source: 0001415889-22-002862 · form4-03102022_050332.xml · nonDerivative · entry 1

Riebman Jerome · CIK 0001825821 · CHIEF MEDICAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,334

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.

F2 · balance_after: Includes 4,552 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.

SEC source: 0001415889-21-005960 · form4-12152021_011220.xml · nonDerivative · entry 1

Englese Thomas · CIK 0001825799 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,088

F1 · balance_after: Includes 508 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.

SEC source: 0001104659-21-148591 · tm2135128-1_4seq1.xml · nonDerivative · entry 2

HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the Kevin L. Rakin Irrevocable Trust

Disclosed balance after: 90,807

SEC source: 0001104659-21-148591 · tm2135128-1_4seq1.xml · nonDerivative · entry 1

HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,862,604

F1 · ownership.nature: Includes: (i) 53,818 shares of Common Stock held of record by HighCape Partners, L.P.; (ii) 4,001,428 shares of Common Stock held of record by HighCape Partners QP, L.P.; (iii) 499,145 shares of Common Stock held of record by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Common Stock held of record by HighCape Co-Investment Vehicle II, LLC; and (v) 48,931 shares of Common Stock held of record by HighCape Capital, L.P.

F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner of HighCape Partners GP, L.P., which is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P.

F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any.

SEC source: 0001826279-23-000002 · primary_doc.xml · derivative · entry 2

HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners QP II, L.P. · CIK 0001770972 · 10% owner

HighCape Partners GP II, LLC · CIK 0001957360 · 10% owner

HighCape Partners GP II, L.P. · CIK 0001957359 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,255,693

Underlying: Class A Common Stock · 4,255,693 shares

Expires not disclosed

F1 · price: The reported securities are included within the 2,837,128 Units purchased by the reporting persons for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock (the "Common Stock") and one warrant to purchase one and one-half shares of Common Stock.

F5 · derivative.expiration_date: The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028.

F6 · ownership.nature: Includes (i) 2,058,623 shares of Common Stock issuable upon exercise of a warrant held by HighCape Partners QP II, L.P.; (ii) 42,954 shares of Common Stock issuable upon exercise of a warrant held by HighCape Partners II, L.P; and (iii) 2,154,116 shares of Common Stock issuable upon exercise of a warrant held by Elutia PIPE Investment, LP.

SEC source: 0001826279-23-000002 · primary_doc.xml · nonDerivative · entry 1

HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners QP II, L.P. · CIK 0001770972 · 10% owner

HighCape Partners GP II, LLC · CIK 0001957360 · 10% owner

HighCape Partners GP II, L.P. · CIK 0001957359 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 8,434,732

F1 · price: The reported securities are included within the 2,837,128 Units purchased by the reporting persons for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock (the "Common Stock") and one warrant to purchase one and one-half shares of Common Stock.

F2 · ownership.nature: Includes: (i) 53,818 shares of Common Stock held of record by HighCape Partners, L.P.; (ii) 4,001,428 shares of Common Stock held of record by HighCape Partners QP, L.P.; (iii) 499,145 shares of Common Stock held of record by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Common Stock held of record by HighCape Co-Investment Vehicle II, LLC; (v) 48,931 shares of Common Stock held of record by HighCape Capital, L.P; (vi) 43,659 shares of Common Stock held of record by HighCape Partners II, L.P.; (vii) 2,092,392 shares of Common Stock held of record by HighCape Partners QP II, L.P.; and (viii) 1,436,077 shares of Common Stock held of record by Elutia PIPE Investment, LP.

F3 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner ("GP") of HighCape Partners GP, L.P., which is the GP of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which is the GP of HighCape Capital, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Partners GP II, LLC, which is the GP of HighCape Partners GP II, L.P., which is the GP of each of HighCape Partners II, L.P., HighCape Partners QP II, L.P. and Elutia PIPE Investment, LP. In addition, HighCape Partners GP, L.P. manages each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC.

F4 · ownership.nature: Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC, and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. In addition, each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held by HighCape Partners II, L.P., HighCape Partners QP II, L.P. and Elutia PIPE Investment, LP. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any.

SEC source: 0001827500-23-000002 · primary_doc.xml · derivative · entry 2

HighCape Capital, LLC · CIK 0001827500 · 10% owner

HighCape Partners II, L.P. · CIK 0001770952 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,255,693

Underlying: Class A Common Stock · 4,255,693 shares

Expires not disclosed

F1 · price: The reported securities are included within the 2,837,128 Units purchased by the reporting persons for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock (the "Common Stock") and one warrant to purchase one and one-half shares of Common Stock.

F5 · derivative.expiration_date: The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028.

F6 · ownership.nature: Includes (i) 2,058,623 shares of Common Stock issuable upon exercise of a warrant held by HighCape Partners QP II, L.P.; (ii) 42,954 shares of Common Stock issuable upon exercise of a warrant held by HighCape Partners II, L.P; and (iii) 2,154,116 shares of Common Stock issuable upon exercise of a warrant held by Elutia PIPE Investment, LP.

SEC source: 0001827500-23-000002 · primary_doc.xml · nonDerivative · entry 1

HighCape Capital, LLC · CIK 0001827500 · 10% owner

HighCape Partners II, L.P. · CIK 0001770952 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 8,434,732

F1 · price: The reported securities are included within the 2,837,128 Units purchased by the reporting persons for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock (the "Common Stock") and one warrant to purchase one and one-half shares of Common Stock.

F2 · ownership.nature: Includes: (i) 53,818 shares of Common Stock held of record by HighCape Partners, L.P.; (ii) 4,001,428 shares of Common Stock held of record by HighCape Partners QP, L.P.; (iii) 499,145 shares of Common Stock held of record by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Common Stock held of record by HighCape Co-Investment Vehicle II, LLC; (v) 48,931 shares of Common Stock held of record by HighCape Capital, L.P; (vi) 43,659 shares of Common Stock held of record by HighCape Partners II, L.P.; (vii) 2,092,392 shares of Common Stock held of record by HighCape Partners QP II, L.P.; and (viii) 1,436,077 shares of Common Stock held of record by Elutia PIPE Investment, LP.

F3 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner ("GP") of HighCape Partners GP, L.P., which is the GP of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which is the GP of HighCape Capital, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Partners GP II, LLC, which is the GP of HighCape Partners GP II, L.P., which is the GP of each of HighCape Partners II, L.P., HighCape Partners QP II, L.P. and Elutia PIPE Investment, LP. In addition, HighCape Partners GP, L.P. manages each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC.

F4 · ownership.nature: Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC, and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. In addition, each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held by HighCape Partners II, L.P., HighCape Partners QP II, L.P. and Elutia PIPE Investment, LP. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any.

SEC source: 0001415889-21-004171 · form4-09012021_010913.xml · derivative · entry 1

Edwards Peter G · CIK 0001578376 · GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,200

Underlying: Class A Common Stock · 96,200 shares

Expires 2031-08-31

F1 · derivative.exercise_date: The option vests as to 25% of the shares on August 31, 2022 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on August 31, 2025.

SEC source: 0001415889-21-002895 · form4-06092021_020617.xml · derivative · entry 2

HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,082

Underlying: Class A Common Stock · 14,082 shares

Expires 2031-06-06

F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date.

F3 · ownership.nature: Held by W. Matthew Zuga as non-employee member of the Issuer's board of directors

SEC source: 0001415889-21-002895 · form4-06092021_020617.xml · derivative · entry 1

HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner

HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner

HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner

HighCape Partners GP, LLC · CIK 0001819933 · 10% owner

HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner

HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner

HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner

HighCape Capital, LLC · CIK 0001827500 · 10% owner

Zuga Matt · CIK 0001790214 · Director · 10% owner

RAKIN KEVIN · CIK 0001184421 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,082

Underlying: Class A Common Stock · 14,082 shares

Expires 2031-06-06

F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date.

F2 · ownership.nature: Held by Kevin L. Rakin as non-employee member of the Issuer's board of directors

SEC source: 0001415889-21-002897 · form4-06092021_020631.xml · derivative · entry 1

Mills C Randal · CIK 0001370939 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,082

Underlying: Class A Common Stock · 14,082 shares

Expires 2031-06-06

F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.

SEC source: 0001415889-21-002899 · form4-06092021_020621.xml · derivative · entry 1

Makes Brigid · CIK 0001375927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,082

Underlying: Class A Common Stock · 14,082 shares

Expires 2031-06-06

F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.

SEC source: 0001415889-21-002901 · form4-06092021_020621.xml · derivative · entry 1

Jordan Maybelle · CIK 0001826123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,082

Underlying: Class A Common Stock · 14,082 shares

Expires 2031-06-06

F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's. board of directors through the applicable vesting date.

SEC source: 0001104659-21-065258 · tm2116094-1_4seq1.xml · nonDerivative · entry 2

Ferguson Matthew · CIK 0001304079 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,300

SEC source: 0001104659-21-065258 · tm2116094-1_4seq1.xml · nonDerivative · entry 1

Ferguson Matthew · CIK 0001304079 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.97 to $11.21. The reporting person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-064573 · tm2115948-1_4seq1.xml · nonDerivative · entry 2

LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,151

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.39. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-064573 · tm2115948-1_4seq1.xml · nonDerivative · entry 1

LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,784

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.20 to $12.18. The reporting person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-034463 · tm219212-4_4seq1.xml · derivative · entry 2

Ferguson Matthew · CIK 0001304079 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,150

Underlying: CLASS A COMMON STOCK · 5,150 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A common stock.

F3 · derivative.exercise_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.

F3 · derivative.expiration_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.

SEC source: 0001104659-21-034463 · tm219212-4_4seq1.xml · derivative · entry 1

Ferguson Matthew · CIK 0001304079 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,900

Underlying: CLASS A COMMON STOCK · 30,900 shares

Expires 2031-03-08

F1 · derivative.exercise_date: This option vests as to 25% of the shares on March 8, 2022, and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2025.

SEC source: 0001104659-21-034467 · tm219212-5_4seq1.xml · derivative · entry 2

LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,288

Underlying: CLASS A COMMON STOCK · 16,288 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A common stock.

F3 · derivative.exercise_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.

F3 · derivative.expiration_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.

SEC source: 0001104659-21-034467 · tm219212-5_4seq1.xml · derivative · entry 1

LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,725

Underlying: CLASS A COMMON STOCK · 97,725 shares

Expires 2031-03-08

F1 · derivative.exercise_date: This option vests as to 25% of the shares on March 8, 2022, and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2025.

SEC source: 0001104659-21-034473 · tm219212-6_4seq1.xml · derivative · entry 2

Englese Thomas · CIK 0001825799 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

Underlying: CLASS A COMMON STOCK · 3,750 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A common stock.

F3 · derivative.exercise_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.

F3 · derivative.expiration_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.

SEC source: 0001104659-21-034473 · tm219212-6_4seq1.xml · derivative · entry 1

Englese Thomas · CIK 0001825799 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: CLASS A COMMON STOCK · 22,500 shares

Expires 2031-03-08

F1 · derivative.exercise_date: This option vests as to 25% of the shares on March 8, 2022, and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2025.

SEC source: 0001104659-21-034460 · tm219212-3_4seq1.xml · derivative · entry 2

Riebman Jerome · CIK 0001825821 · CHIEF MEDICAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,125

Underlying: CLASS A COMMON STOCK · 3,125 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A common stock.

F3 · derivative.exercise_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.

F3 · derivative.expiration_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.